Benitec Biopharma Inc. FY 2026: Revenue $0 EPS $(0.98) — 10-K Summary
Benitec Biopharma Inc. reported a net loss of $45.5M for fiscal 2026, compared with a $37.9M loss in fiscal 2025, with no product revenue recognized in either year and diluted EPS of $(0.98) for FY 2026 versus $(1.05) in FY 2025.Financial HighlightsBusiness HighlightsOriginal SEC Filing: Benitec Bi…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.